Drugs / Autologous human bone marrow cells (hBMCs)
Autologous human bone marrow cells (hBMCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00768066 | Aug 2008 → Aug 2012 | disease related to hematopoietic stem cell transplant, left ventricular failure | University of Miami | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous human bone marrow cells (hBMCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00768066 ↗ |
| Known as | BMCs | “The study compared injection of MSCs (n=19) with placebo (n = 11) and BMCs (n=19) with placebo (n = 10), with 1 year of follow-up.” PMID 24247587 ↗ Jan 2014 |
| Known as | bone marrow mononuclear cells | “This trial compares autologous mesenchymal SCs (MSCs) and whole bone marrow mononuclear cells (BMCs).” PMID 21392602 ↗ Mar 2011 |
| Action | Restore | “designed to replace or repair necrotic, scarred, or dysfunctional myocardium” NCT00768066 ↗ |
| Modality | Cell therapy | “cellular cardiomyoplasty” NCT00768066 ↗ |
| Route | Other | “The injections will be administered transendocardially during cardiac catheterization” NCT00768066 ↗ |